Advances in Tumor Agnostic TRK Inhibitor Therapy and NTRK Fusion Testing

Download All
Gain insights into the latest advances in NTRK fusion testing and recent advances in tumor-agnostic TRK inhibition through expert-guided discussion.
George D. Demetri, MD
Program Director
Alexander Drilon, MD
Pashtoon M. Kasi, MD, MS

Podcast

Listen to George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer audience questions from a series of live CCO Webinars focused on when and how to test for NTRK fusions in solid tumors and best practices in using TRK inhibitors.

George D. Demetri, MD
Program Director
Alexander Drilon, MD Pashtoon M. Kasi, MD, MS
Released: August 14, 2020
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Genentech

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings